DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
James ND, Sydes MR, Clarke NW. et al
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 2016;
387 (10024) 1163-1177
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.